LDS/Medical Tests/Serine and Arginine-rich Splicing Factor 2 (SRSF2) Gene Mutation Analysis

Serine and Arginine-rich Splicing Factor 2 (SRSF2) Gene Mutation Analysis

The SRSF2 gene located at 17q25.1 codes for the SRSF2 protein, a member of the 11 serine/arginine-rich (SR) protein family which plays a vital role in the spliceosome assembly. Spliceosome formation is essential for the removal of introns from the pre-mRNA so as to synthesize accurate and functional proteins. Like other SR proteins, SRSF2 possesses two RNA-binding domains, one at the amino-terminus, and another at the carboxy-terminus where multiple of serine-arginine dipeptide repeats exist. In the course of pre-mRNA splicing, SRSF2 is responsible for exon recognition via interaction between its RNA-binding domains and the exonic splicing enhancer motifs in the pre-mRNA. This molecular interaction is essential for the binding of other proteins including U2AF, to assemble as the U1 snRNP spliceosome. Mutations in the SRSF2 gene may result in defective SR protein formation, resulting in a defective spliceosome, and failure of pre-mRNA alternative splicing.

Mutations in the SRSF2 gene have been documented in 10-15% of myelodysplastic syndrome (MDS), 20-53% of Chronic myelomonocytic leukemia (CMML), 1-3% of Juvenile myelomonocytic leukemia (JMML), 12-40% of atypical CML and 12% of acute myeloid leukemia (AML) cases. Mutations in the SRSF2 gene have been linked to unfavorable shorter overall survival in MDS.

  • Useful in the diagnosis of myelodysplastic syndromes and chronic myelomonocytic leukemia
  • Aids in predicting the prognosis of low-risk to medium-risk myelodysplastic syndrome patients

A positive result indicates the presence of mutations in the SRSF2 gene thus indicating risk and unfavorable prognosis in myelodysplasia.

A negative result indicates the absence of mutations in the SRSF2 gene, however, doesn’t rule out the diagnosis, or risk of myelodysplasia.

Negative for mutations analysis (no mutations or pathogenic variants detected)

Single nucleotide polymorphism by next-generation sequencing (NGS), Allele specific primer extension by Real-time PCR (ARMS), Sanger Sequencing.

Whole blood, ACD (Yellow-top), or EDTA (Lavender-top).

Stability

  • Ambient: 24 hours
  • Refrigerated: 7 days
FTL3, SF3B1, U2AF1 gene mutation analysis, MDS panel flow cytometry, CBC with differential, bone marrow biopsy, comprehensive metabolic panel.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login